Adenocarcinoma of the lung other diagnostic studies: Difference between revisions
Shanshan Cen (talk | contribs) (Created page with "__NOTOC__ {{Adenocarcinoma of the lung}} {{CMG}}; {{AE}} {{SC}} ==Overview== ==References== {{reflist|2}} {{WikiDoc Help Menu}} {{WikiDoc Sources}} Category:Disease C...") |
Shanshan Cen (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Adenocarcinoma of the lung}} | {{Adenocarcinoma of the lung}} | ||
{{CMG}}; {{AE}} {{SC}} | {{CMG}}; {{AE}} {{SC}} | ||
== | ===Molecular Test=== | ||
Molecular tests include epidermal growth factor receptor ([[EGFR]]) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present. | |||
==References== | ==References== | ||
Revision as of 21:46, 4 January 2016
|
Adenocarcinoma of the Lung Microchapters |
|
Differentiating Adenocarcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Adenocarcinoma of the lung other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Adenocarcinoma of the lung other diagnostic studies |
|
Adenocarcinoma of the lung other diagnostic studies in the news |
|
Blogs on Adenocarcinoma of the lung other diagnostic studies |
|
Risk calculators and risk factors for Adenocarcinoma of the lung other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Molecular Test
Molecular tests include epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present.